Counterpoint:第二季中國智能手機出貨量按年跌2.4%
Counterpoint報告顯示,第二季中國智能手機出貨量按年減少2.4%,受季節性因素以及中國補貼政策令廠商提前發布新品所致。華為連續第二個季度成為出貨量之冠,佔比由去年同期的15%上升至18.1%,受惠於中階機型Nova 14系列的強勁表現,以及高階機型的大幅折扣優惠。
vivo在第二季的市佔率為18%,排名第二。OPPO以16.2%排名第三,緊隨其後的是小米(01810.HK)及蘋果(AAPL.US)的15.7%及14.4%。
Counterpoint預計,今年中國市場將實現按年增長,但增長速度將有所放緩,未來將繼續關注全球市場動向,特別是關稅、零件成本上漲以及消費者需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.